Subtype
Malignant Exocrine Pancreas Neoplasm
CI-CAN-00003152Explore in graph →
361 active trials5 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003152Explore in graph →
Clinical trials
931 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (136)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05161013 | A Proof-of-Concept Study Evaluating LINFU™ | completed | N/A | 12 | Adenocyte, LLCINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04305067 | PRECISE: Pancreatic Cancer and Exercise | completed | N/A | 8 | Queen's University, BelfastOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01959139 |
| completed |
| Phase 1 / Phase 2 |
| 126 |
| SWOG Cancer Research NetworkNETWORK |
| 1 |
| Feb 9, 2024 |
| clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04406571 | Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer(CAPANCOVID-19) | completed | — | 700 | CHU de ReimsOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | completed | Phase 1 | 17 | University of NebraskaOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06147154 | Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients | completed | — | 23 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02231723 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | completed | Phase 1 | 139 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04596865 | Recurrence After Whipple's (RAW) Study | completed | — | 1,484 | University Hospital Plymouth NHS TrustOTHER | 8 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT00020345 | Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02767700 | NGS and TME for Evidence-based Treatment of Pancreatic Cancer(PePaCaKa-01) | completed | — | 39 | Karolinska University HospitalOTHER | 0 | Oct 24, 2023 | clinicaltrials |
| NCT01068327 | Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01959672 | Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | completed | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03611556 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | completed | Phase 1 / Phase 2 | 213 | MedImmune LLCINDUSTRY | 4 | Oct 3, 2023 | clinicaltrials |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy(POLO) | completed | Phase 3 | 154 | AstraZenecaINDUSTRY | 12 | Sep 13, 2023 | clinicaltrials |
| NCT03273374 | Intraoperative Radiation Therapy for Resectable Pancreatic Cancer | completed | N/A | 42 | Gangnam Severance HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02427841 | Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04289961 | PDAC Peripheral and Portal Vein Sampling | completed | N/A | 26 | The Christie NHS Foundation TrustOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)(PaTK01) | completed | Phase 1 | 27 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03616431 | Pancreatic Cancer Dietary Assessment Study(PanDA) | completed | — | 112 | The Christie NHS Foundation TrustOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01726582 | Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | completed | Phase 2 | 229 | Medical College of WisconsinOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04050085 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | completed | Phase 1 | 6 | University of California, DavisOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02959164 | Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma | completed | Phase 1 | 36 | Mohammed MilhemOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT01835041 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 1 | 21 | Wake Forest University Health SciencesOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT04990037 | A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma(CAPAFOUR) | completed | Phase 1 | 25 | Cantargia ABINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT03126435 | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX | completed | Phase 3 | 218 | SynCore Biotechnology Co., Ltd.INDUSTRY | 7 | May 6, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04236102 | KEBI-Cyto Study - Use of the Biocartis Idylla | completed | N/A | 55 | Royal Cornwall Hospitals TrustOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT03871959 | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma(CATRIPCA) | completed | Phase 1 | 54 | Centre Leon BerardOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03871790 | Peptide-based Immunization for Colon- and and Pancreas-carcinoma(PICOP-GLOBAL) | completed | — | 50 | CENTOGENE GmbH RostockINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05226572 | Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results(REuBio) | completed | — | 462 | University of BolognaOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT05305001 | Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico | completed | — | 107 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02349867 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | completed | Phase 1 | 23 | Virginia Commonwealth UniversityOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT00981162 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | completed | Phase 1 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02394535 | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2024source: clinicaltrials